[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639405":3},{"organization":4,"outcomesModule":7,"designInfo":105,"detailedDescription":104,"studyPopulation":104,"armGroups":112,"interventions":128,"overallOfficials":138,"centralContacts":142,"locations":151,"responsibleParty":184,"collaborators":187,"id":193,"slug":194,"hasResults":195,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":195,"sex":201,"minAge":202,"maxAge":104,"enrollmentInfo":203,"targetDuration":104,"studyType":206,"phases":207,"briefSummary":209,"conditions":210,"keywords":213,"overallStatus":154,"whyStopped":104,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":229},{"fullName":5,"class":6},"University of Cyprus","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":104},[9],{"measure":10,"description":11,"timeFrame":12},"Percentage dipping in night-time systolic blood pressure (SBP)","Primary health outcome will be the percentage dipping (Dipping %=(\\[Mean Daytime SBP-Mean Night-time BP\\]\u002FMean Daytime SBP)×100) in night-time SBP, that will be assessed at baseline, middle (after 1 month), and at end of the observation period (after 2 months). BP (systolic and diastolic blood pressure) will be recorded using non-invasive continuous cuff-less monitoring with advanced actigraphy for 24 hours at baseline, middle (after 1 month), and end of observation period (after 2 months). For the primary analysis, the impact of each intervention will be compared versus the control group and secondarily, the combined effect of the two intervention groups versus the control group will be assessed.","Percentage dipping (Dipping %=([Mean Daytime SBP-Mean Night-time BP]\u002FMean Daytime SBP)×100) in night-time SBP will be assessed at baseline, middle (after 1 month), and at end of the observation period (after 2 months).",[14,18,22,26,30,33,37,41,44,47,50,53,56,60,64,68,72,76,80,84,88,92,96,100],{"measure":15,"description":16,"timeFrame":17},"Pittsburgh Sleep Quality Index (PSQI)","The Pittsburgh Sleep Quality Index (PSQI) is a self-report questionnaire that assesses sleep quality over a one-month time interval. The PSQI is commonly used in both clinical and research settings to evaluate various aspects of sleep. It is a valuable tool for assessing sleep quality as it captures multiple dimensions of sleep, including both subjective experiences and objective parameters. Higher scores indicate poorer sleep quality, with a score greater than 5 suggesting significant sleep difficulties.","The PSQI will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months)",{"measure":19,"description":20,"timeFrame":21},"Sleep-wake pattern","Sleep-wake pattern will be estimated based on measurements of movement and heart rate obtained from a wearable device (wristband).","Daily measurements - for the whole duration of follow-up (2 months)",{"measure":23,"description":24,"timeFrame":25},"Sleep-Wake self-reported evaluation","The sleep-wake self-reported evaluation will be carried out using a predefined sleep diary which will be completed by the participant on the morning after he\u002Fshe wakes up. Each assessment of sleep-wake self-reported evaluation will be carried out for a whole week.","The sleep-wake self-reported evaluation will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).]",{"measure":27,"description":28,"timeFrame":29},"Hamilton Anxiety Rating Scale","The Hamilton Anxiety Rating Scale will be carried out to assess the severity of a person's anxiety. The Hamilton Anxiety Rating Scale ranges from 0 to 56, where higher scores indicate greater anxiety severity. The scoring is divided into severity tiers: \\\u003C17 (mild), 18-24 (mild to moderate), and 25-56 (moderate to severe). The scale consists of 14 items, each rated from 0 to 4 points. It evaluates both psychic anxiety (e.g., tension, fears, mood) and somatic anxiety (physical complaints).","The Hamilton Anxiety Rating Scale will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months)",{"measure":31,"description":32,"timeFrame":21},"Daily heart rate","Heart rate measurements taken throughout the day by a wearable device (wristband).",{"measure":34,"description":35,"timeFrame":36},"Heart Rate","Heart rate will be measured using ECG.","Heart Rate will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).",{"measure":38,"description":39,"timeFrame":40},"Heart Rate Variability","Heart rate variability will be measured using ECG.","The heart rate variability will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months)",{"measure":42,"description":43,"timeFrame":21},"The personal ambient temperature profile of all participants","Personal exposures of participants will be monitored continuously during the two observation months with wearable sensors to be always worn and assess personal exposure to ambient (indoor and outdoor) temperature (iButton).",{"measure":45,"description":46,"timeFrame":21},"Wet-bulb globe temperature (WGBT)","Wet-bulb globe temperature (WGBT) will be assessed as a thermal stress indicator.",{"measure":48,"description":49,"timeFrame":21},"Humidity","Humidity will be measured using iButton.",{"measure":51,"description":52,"timeFrame":21},"Indoor concentration levels of PM2.5 and PM10 at residence","Particulate matter (PM2.5 and PM10) concentration levels (micrograms per cubic meter of air) at participants' residences will be measured continuously indoors using commercial lightweight sensors (Alpha sense).",{"measure":54,"description":55,"timeFrame":21},"Number of daily steps","Physical activity will be measured as number of daily steps, throughout the day by a wearable device (wristband).",{"measure":57,"description":58,"timeFrame":59},"Serum C-reactive Protein (CRP) levels","Serum levels of CRP (mg\u002FL), as a marker of systemic inflammation, will be measured from each participant at baseline, middle (after 1 month), and at end of observation period (after 2 months).","Serum levels of CRP will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).",{"measure":61,"description":62,"timeFrame":63},"Serum Urea Levels","Serum levels of urea (mg\u002FdL), as a marker of renal function, will be measured from each participant at baseline, middle (after 1 month), and at end of observation period (after 2 months).","Serum levels of urea will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).",{"measure":65,"description":66,"timeFrame":67},"Serum Creatinine Levels","Serum levels of creatinine (mg\u002FdL), as a marker of renal function, will be measured from each participant at baseline, middle (after 1 month), and at end of observation period (after 2 months).","Serum levels of creatinine will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).",{"measure":69,"description":70,"timeFrame":71},"Serum Sodium levels","Serum levels of sodium (mmol\u002FL), as a marker of hydration, will be measured from each participant at baseline, middle (after 1 month), and at end of observation period (after 2 months).","Serum levels of sodium will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).",{"measure":73,"description":74,"timeFrame":75},"Serum Potassium levels","Serum levels of potassium (mmol\u002FL), as a marker of hydration, will be measured from each participant at baseline, middle (after 1 month), and at end of observation period (after 2 months).","Serum levels of potassium will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).",{"measure":77,"description":78,"timeFrame":79},"Serum Osmolality","Serum osmolality (mOsm\u002Fkg), as a marker of hydration, will be measured from each participant at baseline, middle (after 1 month), and at end of observation period (after 2 months).","Serum osmolality will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).",{"measure":81,"description":82,"timeFrame":83},"Urine Creatinine Levels","Urine levels of creatinine (mg\u002FdL), as a marker of renal function, will be measured from each participant at baseline, middle (after 1 month), and at end of observation period (after 2 months).","Urine levels of creatinine will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).",{"measure":85,"description":86,"timeFrame":87},"Urine Sodium levels","Urine levels of sodium (mmol\u002FL), as a marker of hydration, will be measured from each participant at baseline, middle (after 1 month), and at end of observation period (after 2 months).","Urine levels of sodium will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).",{"measure":89,"description":90,"timeFrame":91},"Urine Potassium levels","Urine levels of potassium (mmol\u002FL), as a marker of hydration, will be measured from each participant at baseline, middle (after 1 month), and at end of observation period (after 2 months).","Urine levels of potassium will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).",{"measure":93,"description":94,"timeFrame":95},"Urine Osmolality","Urine osmolality (mOsm\u002Fkg), as a marker of hydration, will be measured from each participant at baseline, middle (after 1 month), and at end of observation period (after 2 months).","Urine osmolality will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).",{"measure":97,"description":98,"timeFrame":99},"Hair cortisol levels","Hair cortisol levels (pg\u002Fmg), as a marker of stress, will be measured from each participant at baseline, middle (after 1 month), and at end of observation period (after 2 months).","Hair cortisol levels will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).",{"measure":101,"description":102,"timeFrame":103},"Saliva alpha-amylase levels","Saliva levels of alpha-amylase (U\u002FmL), as a marker of stress, will be measured from each participant at baseline, middle (after 1 month), and at end of observation period (after 2 months).","Saliva levels of alpha-amylase will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).",null,{"allocation":106,"interventionModel":107,"interventionModelDescription":108,"primaryPurpose":109,"observationalModel":104,"timePerspective":104,"maskingInfo":110},"RANDOMIZED","PARALLEL","Participants will be randomized into three parallel study groups to a) receive no alerts for high temperatures nor recommendations for mitigation of health effects (business as usual scenario, control group), b) receive timely personal alerts for high temperatures and specific recommendations to reduce exposure to heat by changing patterns of time spent and physical activity performed outdoors, regulating indoor temperature using fans and or A\u002FC devices, as well as recommendations for mitigation of health effects (hydration, body cooling) in written and animated format, through mobile phone and web application tools (heat mitigation intervention), and c) receive alerts and recommendations as in group (b) and in addition continuously use air cleaners with HEPA filter for removing PM from indoor air in their residences (heat and air pollution mitigation intervention)","PREVENTION",{"masking":111,"maskingDescription":104,"whoMasked":104},"NONE",[113,117,123],{"label":114,"type":115,"description":116,"interventionNames":104},"Control group","NO_INTERVENTION","Subjects in this arm will receive no alerts for high temperatures nor recommendations for mitigation of heat-related health effects.",{"label":118,"type":119,"description":120,"interventionNames":121},"Heat intervention - Personal Alerts and Specific Recommendations","EXPERIMENTAL","Subjects in this group will receive timely personal alerts for high temperatures and specific recommendations to reduce exposure to heat and mitigation of heat-related health effects in written and animated format through mobile phones, mobile applications and online tools.",[122],"Behavioral: Heat intervention",{"label":124,"type":119,"description":125,"interventionNames":126},"Heat and air pollution intervention - Group Alerts, Recommendations and Air Cleaners","Subjects in this group will receive alerts and recommendations as in group \"Heat intervention\" and in addition, continuously use of air cleaners with HEPA filter for removing PM from indoor air in their residences and workplaces to provide evidence for health benefits.",[127],"Behavioral: Heat and air pollution mitigation intervention",[129,134],{"type":130,"name":131,"description":132,"armGroupLabels":133,"otherNames":104},"BEHAVIORAL","Heat intervention","The participants in this group of intervention will receive timely personal alerts for high temperatures and specific recommendations to reduce exposure to heat by changing patterns of time spent and physical activity performed outdoors, regulating indoor temperature using fans and\u002For air conditioning devices, as well as recommendations for mitigation of heat-related health effects (hydration, body cooling) in written and animated format, through mobile phones, web application and online tools to be developed by the project research team.",[118],{"type":130,"name":135,"description":136,"armGroupLabels":137,"otherNames":104},"Heat and air pollution mitigation intervention","The participants in this intervention group will receive alerts and recommendations as in group \"Heat intervention\" and, in addition, continuously use air cleaners with HEPA filters for removing PM from indoor air in their residences and workplaces",[124],[139],{"name":140,"affiliation":5,"role":141},"Panayiotis Yiallouros, Professor","PRINCIPAL_INVESTIGATOR",[143,147],{"name":140,"role":144,"phone":145,"phoneExt":104,"email":146},"CONTACT","+35722895212","yiallouros.panayiotis@ucy.ac.cy",{"name":148,"role":144,"phone":149,"phoneExt":104,"email":150},"Panayiotis Kouis, PhD","+35722895243","kouis.panayiotis@ucy.ac.cy",[152,166],{"facility":153,"status":154,"city":155,"state":104,"zip":104,"country":156,"countryCode":157,"cosmosGeoPoint":158,"geoPoint":163,"contacts":164},"Medical School, University of Cyprus","RECRUITING","Nicosia","Cyprus","CY",{"type":159,"coordinates":160},"Point",[161,162],33.35397,35.17284,{"lat":162,"lon":161},[165],{"name":148,"role":144,"phone":149,"phoneExt":104,"email":150},{"facility":167,"status":154,"city":168,"state":104,"zip":104,"country":169,"countryCode":170,"cosmosGeoPoint":171,"geoPoint":175,"contacts":176},"Vall d'Hebron Institut de Recerca (VHIR)","Barcelona","Spain","ES",{"type":159,"coordinates":172},[173,174],2.15899,41.38879,{"lat":174,"lon":173},[177,181],{"name":178,"role":144,"phone":179,"phoneExt":104,"email":180},"Aida Ribera, PhD","+34 93 2594263","ariberas@perevirgili.cat",{"name":182,"role":144,"phone":179,"phoneExt":104,"email":183},"Cristina Vert Roca, PhD","cristina.vert@vhir.org",{"type":141,"investigatorFullName":185,"investigatorTitle":186,"investigatorAffiliation":5,"oldNameTitle":104,"oldOrganization":104},"Panayiotis Yiallouros","Professor",[188,191],{"name":189,"class":190},"FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA","UNKNOWN",{"name":192,"class":190},"PANCYPRIAN FEDERATION OF LABOUR","100639405","mitigation-of-health-effects-in-older-adults-with-hypertension-by-reducing-exposure-to-heat-and-air-pollution-100639405",false,"NCT07606859","Mitigation of Health Effects in Older Adults With Hypertension by Reducing Exposure to Heat and Air Pollution","Innovative Solutions Across the MEDiterranean for Mitigation of Climate Change-related heaLth rIsks and Enhancing Health systeM Resilience","ISMED CLIM OH","Inclusion Criteria:\n\n* Aged ≥65 years\n* Living in Barcelona (Spain) or Nicosia (Cyprus) metropolitan areas\n* Have a physician's diagnosis of arterial hypertension\n* Receive daily anti-hypertensive medication\n* Clinically stable\n\nExclusion Criteria:\n\n* Currently smoking\n* Presence of any smoking residents in the household\n* Not residing at the household for at least 5 days a week\n* Planning to move from the current home within the next two months\n* No access to Wi-Fi or 4G\u002F5G mobile phone\n* Severe chronic conditions (congestive heart failure, ischemic heart disease, significant valvular heart disease, diabetes mellitus type 2 (DM2), inflammatory diseases, renal failure, or active cancer)\n* Illicit drugs abuse\n* Alcohol abuse\n* Psychiatric disorders\n* Severe mental disability that interferes with answering questions or following instructions","ALL","65 Years",{"count":204,"type":205},102,"ESTIMATED","INTERVENTIONAL",[208],"NA","The goal of this clinical trial is to assess the effectiveness of an intervention (combination of behavioural recommendations and technical measures) in reducing personal exposure to heat and air pollution and related health effects in older adults with hypertension.\n\nThe main questions it aims to answer are:\n\n* Does the intervention (combination of behavioral recommendations for heat mitigation) reduce personal ambient temperature exposure, measured using a wearable device (iButton)?\n* Does the intervention (combination of behavioral recommendations for air pollution mitigation and use of indoor air cleaners) reduce indoor exposure to air pollution, measured using indoor air quality sensors (Purple Air)?\n* Does the intervention (combination of behavioral recommendations for heat mitigation) improve the abnormalities in circadian blood pressure variation experienced by older adults with hypertension, assessed using advanced actigraphy? Researchers will compare measurements between older adults with hypertension carrying out their daily activities in the absence of intervention (control group), those carrying out their daily activities with behavioural recommendations (recommendation intervention group) and those carrying out their daily activities with both behavioural recommendations for heat mitigation and continuous use of indoor air cleaners in their house (heat and air pollution mitigation intervention group) to see if changes in temperature exposure and sleep are different between intervention groups.\n\nParticipants will:\n\n* Wear the wearable devise for continuous personal ambient temperature monitoring (ibutton) daily for a period of three months\n* Have their core temperature measured using an eCelsius medical capsule in three repeated assessments\n* Have their blood pressure, oxygen saturation, ECG and heart rate variability measured using 24-hour advanced actigraphy in three repeated assessments\n* Provide samples of urine and blood biomarkers in three repeated assessments.",[211,212],"Hypertension Arterial","65 Years Older",[214,215,216,217,218,219],"Hypertension","Adults 65 years and older","Intervention","Personal Ambient Temperature Exposure","Indoor air quality","Indoor air purification","2026-06-03",{"date":222,"type":223},"2026-06-05","ACTUAL",{"date":225,"type":223},"2026-05-01",{"date":227,"type":205},"2027-07-31",{"name":5,"class":6},2]